aInstitute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin, Berlin, Germany
bDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
cDepartment of Medical Biometry and Epidemiology, University Medical Center, Hamburg-Eppendorf
dKlinik am See, Rehabilitation Center for Cardiovascular Diseases, Rüdersdorf
eCenter of Rehabilitation Research, University Potsdam, Potsdam, Germany
Correspondence to Reinhold Kreutz, Institut für Klinische Pharmakologie und Toxikologie, Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin D-10117, Germany. Tel: +49 30 450 525 112; fax: +49 30 450 7 525 112; e-mail: [email protected]
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; EGFR, estimated glomerular filteration rate; FGF23, fibroblast growth factor 23; GWAS, genome-wide association studies; LVED, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMI, left ventricular mass index; MAF, minor allele frequency; MI, myocardial infarction; NKCC2, Na-K-2Cl cotransporter; RWT, relative wall thickness; SNP, single nucleotide polymorphism; TAL, thick ascending limb; UMOD, uromodulin
Received 10 November, 2016
Revised 26 February, 2017
Accepted 10 May, 2017
